For the Treatment of Chronic Obstructive Pulmonary Disease, the Highest Percentage of Surveyed Pulmonologists Consider Spi

However, in Contrast to Surveyed Pulmonologists, Surveyed MCO Pharmacy Directors Were More Evenly Divided Between Spiriva and Advair/Seretide/Adoair as Being the Most Efficacious COPD Therapy, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of chronic obstructive pulmonary disease (COPD), the highest percentage of surveyed pulmonologists (52 percent) consider Boehringer Ingelheim/Pfizer’s Spiriva (tiotropium) to be the most efficacious therapy, when compared to other currently available agents. Although GlaxoSmithKline’s Advair/Seretide/Adoair (salmeterol/fluticasone propionate) was the COPD market sales leader in 2009, only 38 percent of surveyed pulmonologists selected it as the most efficacious therapy. Surveyed pulmonologists who selected either Spiriva or Advair/Seretide/Adoair were most satisfied with these agents’ efficacy in improving quality of life and reducing dyspnea.

The findings from Decision Resources’ analysis of the COPD drug market reveal that while sales of Spiriva for COPD in 2009 were strong, Advair/Seretide/Adoair likely led the market owing to its premium price and because of higher prescribing rates among primary care physicians/general practitioners in many countries. However, in contrast to surveyed pulmonologists, surveyed managed care organizations’ (MCOs) pharmacy directors were more evenly divided between Advair/Seretide/Adoair and Spiriva as being the most efficacious COPD therapy. Forty-five percent of surveyed MCO pharmacy directors cited Advair/Seretide/Adoair as the most efficacious and 40 percent selected Spiriva.

“In addition to its sales-leading position in the COPD market, Advair/Seretide/Adoair is the sales-leading therapy for asthma,” said Decision Resources Benjamin Guikema, Ph.D. “Surveyed pharmacy directors who chose Advair/Seretide/Adoair may be responding to its efficacy in asthma as well as in COPD.”

The findings also reveal that only eight percent of surveyed physicians and ten percent of surveyed pharmacy directors chose AstraZeneca/Astellas Pharma’s Symbicort (formoterol/budesonide) as the most efficacious therapy for COPD. This response likely reflects the relatively recent entry of this combination into the COPD drug market (it was approved for the indication in 2009 in the United States and Europe) and the lack of long-term postmarketing studies showing its effect on reducing exacerbations.

The COPD drug market will increase from nearly $8.4 billion in 2009 to more than $13 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. An expanding aging population and increases in diagnosis and drug treatment will fuel market growth as the drug-treated population is expected to expand from nearly 18 million patients in 2009 to nearly 24 million patients in 2019 in the world’s major pharmaceutical markets.

Decision Resources’ Robust Market Forecast and Opportunities Analysis

Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2011 advisory service and the DecisionBase 2011 report series.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Cardiology  Pharmaceutical  Other Health  General Health  Managed Care

MEDIA:

Logo
 Logo

Suggested Articles

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.

ICER said that Vertex's triplet CF therapy Trikafta would only be cost effective if the price were dropped from $311,000 to no more than $85,500.